Browse > Article
http://dx.doi.org/10.4046/trd.2010.69.2.115

A Case of Ischemic Colitis Associated with Paclitaxel Loaded Polymeric Micelle ($Genexol-PM^{(R)}$) Chemotherapy  

Park, Choel-Kyu (Department of Internal Medicine, Chonnam National University Medical School)
Kang, Hyun-Wook (Department of Internal Medicine, Chonnam National University Medical School)
Kim, Tae-Ok (Department of Internal Medicine, Chonnam National University Medical School)
Ki, Ho-Seok (Department of Internal Medicine, Chonnam National University Medical School)
Kim, Eun-Young (Department of Internal Medicine, Chonnam National University Medical School)
Ban, Hee-Jung (Department of Internal Medicine, Chonnam National University Medical School)
Yoon, Byeong-Kab (Department of Internal Medicine, Chonnam National University Medical School)
Oh, In-Jae (Department of Internal Medicine, Chonnam National University Medical School)
Choi, Yoo-Deok (Department of Pathology, Chonnam National University Medical School)
Kwon, Yong-Soo (Department of Internal Medicine, Chonnam National University Medical School)
Kim, Yoo-Il (Department of Internal Medicine, Chonnam National University Medical School)
Lim, Sung-Chul (Department of Internal Medicine, Chonnam National University Medical School)
Kim, Young-Chul (Department of Internal Medicine, Chonnam National University Medical School)
Kim, Kyu-Sik (Department of Internal Medicine, Chonnam National University Medical School)
Publication Information
Tuberculosis and Respiratory Diseases / v.69, no.2, 2010 , pp. 115-118 More about this Journal
Abstract
Paclitaxel has been widely used for treating many solid tumors. Although colonic toxicity is an unusual complication of paclitaxel-based chemotherapy, the reported toxicities include pseudomembranous colitis, neutropenic enterocolitis and on rare occasions ischemic colitis. $Genexol-PM^{(R)}$, which is a recently developed cremophor-free, polymeric micelle-formulated paclitaxel, has shown a more potent antitumor effect because it can increase the usual dose of paclitaxel due to that $Genexol-PM^{(R)}$ does not include the toxic cremophor compound. We report here on a case of a 57-year-old man with advanced non-small cell lung cancer and who developed ischemic colitis after chemotherapy with $Genexol-PM^{(R)}$ and cisplatin. He complained of hematochezia with abdominal pain on the left lower quadrant. Colonoscopy revealed diffuse mucosal hemorrhage and edema from the sigmoid colon to the splenic flexure. After bowel rest, he recovered from his symptoms and the follow-up colonoscopic findings showed that the mucosa was healing. Since then, he was treated with pemetrexed monotherapy instead of a paclitaxel compound and platinum.
Keywords
Paclitaxel; Genexol-PM; Colitis, Ischemic;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191-202.   DOI   ScienceOn
2 Sreenarasimhaiah J. Diagnosis and management of ischemic colitis. Curr Gastroenterol Rep 2005;7:421-426.   DOI   ScienceOn
3 Seewaldt VL, Cain JM, Goff BA, Tamimi H, Greer B, Figge D. A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. Gynecol Oncol 1997;67:137-140.   DOI   ScienceOn
4 Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995;95:1869-1876.   DOI   ScienceOn
5 Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-86.
6 Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:2009-2014.   DOI   ScienceOn
7 Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996;14:2054-2060.   DOI
8 Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-1598.   DOI   ScienceOn
9 Tashiro M, Yoshikawa I, Kume K, Otsuki M. Ischemic colitis associated with paclitaxel and carboplatin chemotherapy. Am J Gastroenterol 2003;98:231-232.   DOI   ScienceOn
10 Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-3716.   DOI   ScienceOn